Theriva Biologics, Inc. announced its financial results for the fiscal year ended December 31, 2025, highlighting a cash position of $13.1 million and advancements in clinical development, including licensing SYN-020 to Rasayana Therapeutics.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.